Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14thGlobeNewsWire • 09/09/22
Wall Street Analysts See an 114% Upside in Immunovant, Inc. (IMVT): Can the Stock Really Move This High?Zacks Investment Research • 08/30/22
Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022GlobeNewsWire • 08/24/22
Wall Street Analysts Think Immunovant, Inc. (IMVT) Could Surge 142%: Read This Before Placing a BetZacks Investment Research • 08/10/22
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022GlobeNewsWire • 08/05/22
Why Is Immunovant, Inc. (IMVT) Up 13.9% Since Last Earnings Report?Zacks Investment Research • 07/08/22
Immunovant, Inc. (IMVT) CEO Pete Salzmann on Q4 2022 Results - Earnings Call TranscriptSeeking Alpha • 06/09/22
Immunovant To Start Pivotal Batoclimab Trials In Thyroid Eye Disease Later This YearBenzinga • 06/08/22
Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022GlobeNewsWire • 06/08/22
Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022GlobeNewsWire • 06/06/22
Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25thGlobeNewsWire • 05/23/22
Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/09/22
Immunovant: Speculative Biotech With Proven Class Of Drugs Targeting FcRn PathwaySeeking Alpha • 02/05/22